基因修饰的骨髓间充质干细胞移植治疗帕金森病的研究进展

Research Progress of Genetic Modified Bone Marrow Mesenchymal Stem Cell Transplantation for the Therapy of Parkinson’s Disease

帕金森病进展缓慢,以神经退化为特征,主要病因是选择性中脑黑质多巴胺能神经元的丧失和纹状体多巴胺含量的显著减少。传统疗法有药物治疗和外科治疗,而近来较理想是基因治疗和干细胞移植治疗,包括胚胎干细胞、神经干细胞和间充质干细胞等。骨髓间充质干细胞作为体内一种多功能干细胞,具有成为基因治疗靶细胞的显著优势,并已被普遍用于人类疾病的研究。然而,对帕金森病进行基因治疗的目的基因选择具有多样性。因此,本文主要针对近十年基因治疗帕金森病的目的基因的选择相关研究进展作一综述。

Parkinson’s disease (PD) is a neurodegenerative disease characterized by progressive degeneration of nigrostriatal dopaminergic (Dopamine, DA) neurons and reduced concentration of striatal dopamine. Traditional therapies for Parkinson’s disease are medication and surgery, while gene therapy and stem-cell therapy have been considered as much more ideal methods recently, such as embryonic stem cells, neural stem cells and mesenchymal stem cells, etc. Bone mesenchymal stem cells as a kind of pluripotent stem cells in the body are widely used in the related human diseases for the superiority to be the target cells of gene therapy. However, choosing appropriate target genes for therapy of Parkinson’s disease has a great diversity, therefore, here I summarize the researches of the theraphy methods of Parkinson’s disease in recent 10 years.